Demand for glucagon-like peptide-1 therapies has never been clearer. Yet for obesity-indicated GLP-1s, 90 percent of that demand never becomes treatment. Payer rejections, cost concerns and early drop-off drown out the signal between a written prescription and a patient on therapy.
The pressure lands on pharmacy. Patients diagnosed with obesity face a 40 percent rejection rate on GLP-1 claims. Anti-obesity therapies carry an average out-of-pocket cost of $164, nearly three times the $59 diabetes patients pay.
This report traces where the static creeps in between prescribing and persistence and what pharmacy and access teams can do about it.
Inside the report:
- Why GLP-1 demand leaks happen and how to strengthen first-fills and therapy persistence
- Why obesity coverage lags diabetes and how comorbidity-specific prescribing may lift claim approvals
- How sticker shock at the pharmacy counter sends patients home empty-handed and how to address cost barriers early
